|Videos|June 8, 2020

Has the COVID 19 Political Response Been Responsive to ID Experts?

Author(s)Contagion&reg Editorial Staff

Mary Schmidt, MD, discusses challenges in translating infectious disease advice to policy action.

Segment Description: Mary Schmidt, MD, associate professor of Clinical Medicine at Virginia Commonwealth University, Inova Fairfax Campus, discusses challenges in translating infectious disease advice to policy action.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Latest CME

Audio

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

Virtual Event

Kansas Society of Clinical Oncology

2 Sessions are Available!

Virtual Event

North Carolina Oncology Association

2 Sessions are Available!

Has the COVID 19 Political Response Been Responsive to ID Experts?

Related Content

Efflux Pump Inhibitor Restores Azithromycin Activity Against Multidrug-Resistant Gram-Negative Pathogens

mRNA-based Influenza Vaccine Advances Against HHS Resistance

Vaccine for Lassa Fever Succeeds in First-in-Human Trial

Review of Cefepime and Zidebactam: A Novel Antibiotic Approved to Treat Complicated Urinary Tract Infections

FDA Expands Merck Pneumococcal Vaccine Indication to Include At-Risk Children and Adolescents

Latest CME

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Kansas Society of Clinical Oncology

North Carolina Oncology Association

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Breaking the Demodex Blepharitis Cycle: The Importance of Early Intervention

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Southern California Psychiatry Conference

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

25th Annual International Congress on the Future of Breast Cancer® East

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Retina Updates in Montréal

25th Annual International Congress on the Future of Breast Cancer® West

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rhode Island Oncology Society

Kentucky Society of Clinical Oncology

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

27th Annual International Lung Cancer Congress®

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management